Tempus AI (TEM) Could Be 3% Above Fair Value On New Pharma Data Deals

Recent contracts with Bristol Myers Squibb and Pathos AI have pushed Tempus AI (TEM) further into long-term data licensing for oncology and neuroscience, putting its multimodal datasets and Lens platform in sharper investor focus.

Those agreements have landed during a period of sharp share price swings for Tempus AI. The stock has a 1-day share price return of 1.61% and a 7-day share price return of 15.12%, while the 30-day share price return declined 4.96%. However, the 90-day share price return of 77.43% and year-to-date share price return of 24.82% point to strong recent momentum even as the 1-year total shareholder return is down 13.37% at a latest share price of $77.84. This suggests that recent contract news and product updates may be reshaping how investors weigh its growth potential against ongoing risks.

Scan beyond Tempus AI to see how it compares with 36 healthcare AI stocks that are also signing big-ticket data deals and pushing AI deeper into drug development.

Bulls see Tempus AI as a rare data and AI platform with deep pharma buy in. Bears see a loss-making lab business riding a volatile story. Which version does the current valuation lean toward?

Most Popular Narrative: 2.9% Overvalued

Tempus AI closed at $77.84 compared with a narrative fair value of $75.68. The most followed thesis on the stock sees only a modest premium and focuses heavily on how its data and AI loop could change the business over time.

Tempus AI isn't simply an AI software business (not another ChatBot). It is building a healthcare data platform where diagnostics, genomic testing, clinical data, and AI applications reinforce each other through a powerful network effect.

The company generates revenue from multiple sources. Its Diagnostics business performs genomic testing for patients and providers, while its Data and Applications segment sells access to its massive de-identified datasets and AI powered tools to pharmaceutical companies, researchers, and healthcare organizations. Every new test and partnership adds more data, making its AI models more valuable and creating opportunities to cross sell additional products and services.

See why 31 investors see Tempus AI as 3% overvalued.

Result: Fair Value of $75.68 (OVERVALUED)

Still, Tempus AI faces real pressure if high expectations for its AI data flywheel fade or if losses deepen from its US$254.425 million net loss.

Find out about the key risks to this Tempus AI narrative.

Next Steps

Mixed signals around Tempus AI's promise and risk profile make this a good moment to stress test the numbers yourself and decide where you stand. To weigh both sides quickly, start with the 1 key reward and 3 important warning signs.

Looking for more Tempus AI sized opportunities?

If Tempus AI has sharpened your thinking, do not stop here. Use focused screeners to uncover fresh ideas before they move beyond your reach.

• Target resilience first by scanning for companies with strong finances through the list of solid balance sheet and fundamentals (23 results).
• Hunt for quality at a discount by running the 30 high quality undervalued stocks before prices better reflect their fundamentals.
• Lean into stability and income potential by reviewing the 7 dividend fortresses that could complement higher risk ideas in your portfolio.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com